三联活菌制剂调理肠道菌群改善帕金森病患者便秘、焦虑及睡眠
| 作者: |
1王少颖,
1王莉迪,
1曹玉娇,
1李净兵,
1赵璨,
1刘翠青,
1王青青
1 河北省老年病医院神经内科，石家庄 050000 |
| 通讯: |
王少颖
Email: wsyww228@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.11.019 |
| 基金: | 河北省卫生与健康委员会重点科技研究计划(20190980)。 |
摘要
目的：研究三联活菌制剂调理肠道菌群对帕金森病(Parkinson’s disease，PD)患者便秘症状及焦虑睡眠状态的改善作用。方法：选取河北省老年病医院神经内科收治的39例PD患者，随机分为对照组(常规治疗)19例和联合组(常规治疗+三联活菌制剂调理肠道菌群)20例。比较两组患者治疗前后统一帕金森病症状评分量表(Unified Parkinson’s Disease Rating Scale，UPDRS)-III、便秘患者临床评分量表(Cleveland Clinic Score，CCS)、汉密尔顿焦虑量表(Hamilton Anxiety Scale，HAMA)、汉密尔顿抑郁量表(Hamilton Depression Scale，HAMD)、简易精神状态评定量表(Mini-Mental State Examination，MMSE)、匹兹堡睡眠质量指数(Pittsburgh Sleep Quality Index，PSQI)、日常生活活动能力(Activity of Daily Living Scale，ADL)评分及不良反应发生情况等差异。结果：治疗后4个月，两组患者UPDRS-III量表评分较治疗前均明显下降(P<0.05)；联合组治疗后4个月UPDRS-III量表评分较治疗前明显下降，且联合组治疗后1，4个月UPDRS-III评分较对照组均明显下降(P<0.05)。治疗后4个月，对照组HAMD和PSQI评分较治疗前均明显下降，MMSE和ADL评分较治疗前均明显升高(P<0.05)，CCS和HAMA评分与治疗前比较，差异均无统计学意义(P>0.05)。治疗后4个月，联合组CCS，HAMA，HAMD及PSQI评分较治疗前均明显下降，MMSE和ADL评分较治疗前均明显升高(P<0.05)；相比对照组，联合组治疗后4个月CCS，HAMA，HAMD及PSQI评分均明显下降(P<0.05)。两组患者不良反应发生率的比较，差异无统计学意义(P>0.05)。结论：早期采取三联活菌制剂调理肠道菌群可明显减轻PD患者便秘症状，缓解PD患者焦虑、抑郁等不良心理状态，提高其睡眠质量，从而提高患者的生活质量，值得临床应用。
关键词：
帕金森病；三联活菌制剂；肠道菌群；便秘；睡眠质量
Improvement of constipation, anxiety and sleep of Parkinson’s disease patients by regulating intestinal flora with triple active bacteria preparation
CorrespondingAuthor: WANG Shaoying Email: wsyww228@126.com
DOI: 10.3978/j.issn.2095-6959.2020.11.019
Foundation: This work was supported by the Key Science and Technology Research Program of Hebei Health and Health Commission, China (20190980).
Abstract
Objective: To study the improvement of constipation, anxiety and sleep of Parkinson’s disease (PD) patients by regulating intestinal flora with triple viable agents. Methods: Eighty patients with PD were randomly divided into a control group (conventional treatment) and a combined group (conventional treatment + triple viable agents to regulate intestinal flora), 40 in each group. The unified Parkinson’s disease rating scale (UPDRS)-III, Cleveland Clinic Score (CCS), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Mini-Mental State Examination (MMSE), Pittsburgh sleep quality index (PSQI), Activity of Daily Living Scale (ADL) and adverse reactions were compared between the two groups before and after treatment. Results: Two months after treatment, the UPDRS-III score of the two groups was significantly lower than that before treatment (P<0.05); the UPDRS-III score of the combined group was significantly lower than that before treatment, and the UPDRS-III score of the combined group was significantly lower than that of the control group (P<0.05). Two months after treatment, the scores of HAMD and PSQI in the control group were significantly decreased in comparison of before treatment, MMSE and ADL were significantly higher than before treatment (P<0.05), CCS and HAMA scores showed no significant difference compared with before treatment (P>0.05). The scores of CCS, HAMA, HAMD and PSQI in the combined group were significantly decreased in comparison of those before treatment, and the scores of MMSE and ADL were significantly higher than those before treatment (P<0.05); compared with the control group, the scores of CCS, HAMA, HAMD and PSQI in the combined group were significantly lower in the two months after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Early treatment of intestinal flora with triple viable agents can significantly reduce constipation symptoms, relieve anxiety, depression and other adverse psychological states, improve sleep quality, thus help to improve the quality of life, so it is worth clinical application.
Keywords：
Parkinson’s disease; triple viable agents; intestinal flora; constipation; sleep quality